The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro.
OBJECTIVE
AMD3100, an antagonist of the CXCR4 chemokine receptor is soon to be used clinically for the peripheral mobilization of hematopoietic stem cells (HSCs) in patients with multiple myeloma. AMD3100 has been shown to activate a G protein coupled with CXCR4 and thus acts as a partial CXCR4 agonist in vitro. Thus, we explored whether AMD3100 affected the survival and proliferation of myeloma cells in vitro.


METHODS
The effects of AMD3100 on survival and proliferation of two myeloma cell lines (RPMI8226 and U266) as well as CD138+ cells obtained from several patients with multiple myeloma were analyzed by flow cytometry using annexin V and a colorimetric cell proliferation assay (CCK-8 assay).


RESULTS
AMD3100, but not T140, another CXCR4 antagonist, stimulated the proliferation of myeloma cell lines and CD138+ primary human myeloma cells (-2-fold increase) in a dose-dependent manner in serum-free culture for up to 5 days, which was inhibited by pretreating the cells with pertussis toxin. AMD3100 enhanced the proliferation of U266 cells induced by interleukin-6 and partially reversed AG490-mediated growth inhibition and apoptosis induced by serum deprivation in RPMI8226 cells. AMD3100 induced the phosphorylation of Akt and MAPK p44/p42 in U266 cells and MAPK p44/p42 in RPMI8226 cells. In contrast, AMD3100 markedly increased the cell apoptosis and reduced the number of RPMI8226 cells after 5 to 7 days of culture under serum-free conditions.


CONCLUSIONS
AMD3100 exerts dual effects, initially enhancing and subsequently inhibiting the survival and proliferation of myeloma cells, signaling via CXCR4 in vitro.
Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Ha-Yon
HY
Kim
Ji-Young
JY
Hwang
Seong-Woo
SW
Kim
Hyo-Jin
HJ
Lee
Hwan-Jung
HJ
Yun
Samyong
S
Kim
Deog-Yeon
DY
Jo
J Mol Histol. 2004 Mar;35(3):233-45
15339043
Blood. 2001 Jan 15;97(2):346-51
11154207
J Biol Chem. 2002 Jul 5;277(27):24515-21
11923301
Blood. 2009 Apr 30;113(18):4341-51
19139079
Mol Cancer Ther. 2002 May;1(7):539-44
12479272
Blood. 2009 Jun 11;113(24):6206-14
19050309
Cancer Res. 2006 Oct 1;66(19):9714-21
17018630
World J Gastroenterol. 2008 Apr 21;14(15):2308-13
18416455
J Bone Miner Res. 2009 Jul;24(7):1150-61
19335218
Blood. 2006 May 1;107(9):3772-8
16439684
Br J Haematol. 2005 Apr;129(2):248-56
15813853
Haematologica. 2006 Feb;91(2):200-6
16461304
Leukemia. 2008 Dec;22(12):2151-5158
18769446
J Clin Oncol. 2005 Jun 1;23(16):3871-2; author reply 3872-3
15923599
Leuk Res. 2007 Nov;31(11):1553-63
17403536
Science. 1999 Feb 5;283(5403):845-8
9933168
Oncogene. 2002 Sep 26;21(43):6587-97
12242656
Leukemia. 2001 May;15(5):752-6
11368435
J Immunol. 2007 May 1;178(9):5888-98
17442973
Transfusion. 2005 Mar;45(3):295-300
15752146
J Immunol. 2001 Oct 15;167(8):4686-92
11591799
J Biol Chem. 2003 Nov 21;278(47):47136-44
12958314
Cancer Res. 2005 Jul 1;65(13):5864-71
15994964
Blood. 2005 May 15;105(10):3793-801
15677562